Patrick Verheyen - 11 Apr 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Patrick Verheyen by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
11 Apr 2023
Net transactions value
$0
Form type
4
Filing time
13 Apr 2023, 16:42:47 UTC
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 11 Apr 2023 Common Stock 40,000 $3.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.